In addition, the use of SMO and GLI inhibitors, which negatively affect the Hh signaling pathway, has been shown to be of benefit to patients with carcinomas; nonetheless, little is known regarding the mechanisms that cause carcinomas to have a continuous dependency on the Hh cellular pathway, nor of its impact on tumor progression and therapy response to treatment schemes in patients with lung cancer [84, 91]. The gene discussed is SMO; the disease is lung carcinoma.